Oral sildenafil in skin ulcers secondary to systemic sclerosis

Scandinavian Journal of Rheumatology

Volumn 40, Issue 4, 2011, Pages 323-325

  Della Rossa, A ^a,b   Doveri, M ^a   D'Ascanio, A ^a   Tavoni, A ^a   Consensi, A ^a   Neri, R ^a   Bazzichi, L ^a   Bombardieri, S ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BOSENTAN; CENTROMERE ANTIBODY; ILOPROST; RIBONUCLEOPROTEIN; SCL 70 ANTIBODY; SILDENAFIL;

ADD ON THERAPY; ADULT; AGED; CLINICAL ARTICLE; DISEASE DURATION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LETTER; LOADING DRUG DOSE; MALE; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RAYNAUD PHENOMENON; SKIN ULCER; STATISTICAL ANALYSIS; STATISTICS; SYSTEMIC SCLEROSIS; TREATMENT DURATION; VISUAL ANALOG SCALE; WILCOXON SIGNED RANKS TEST;

ADMINISTRATION, ORAL; ADULT; AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FINGERS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PURINES; SCLERODERMA, SYSTEMIC; SKIN ULCER; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 80052008587     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.569755     Document Type: Letter

References (10)

1. Guiducci S, Giacomelli R, Matucci-Cerinic M. Vascular complications of scleroderma. Autoimmun Rev 2007;6:520-23 (Pubitemid 47374612)
2. Sunderkotter C, Herrgott I, Bruckner C. Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 2009;160:835-43
3. Wigley FM, Seibold JR, Wisc RA. Intravenous iloprost treatment of Raynauds phenomenon for ischaemic ulcers secondary to systemic sclerosis. J Rheumatol 1992;19:1407-13
4. Kowal-Bielecka O, Landewe R, Avouac J, Chwiesko S, Miniati I, Czirjak L, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009;68:620-8
5. Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2004;50:3985-93 (Pubitemid 39643947)
6. De La Vega A, Derk CT. Phosphodiesterase-5 inhibitors for the treatment of Raynauds: a novel indication. Expert Opin Invest Drug 2009;18:23-9
7. Fries R, Shariat K, von Wilmowsky H, Bohm M. Sildenafil in the treatment of Raynauds phenomenon resistant to vasodilatory therapy. Circulation 2005;112:2980-5 (Pubitemid 41612301)
8. Pakodzi A, Howell K, Black CM. Addition of the short-term phosphodiesterase- 5 inhibitor sildenafil to iloprost therapy for scleroderma digital vasculopathy. Arthritis Rheum 2007;56(Suppl):825
9. Brueckner C, Becker MO, Kroencke T, Huscher D, Scherer HU, Worm M, et al. Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study. Ann Rheum Dis 2010;69:1475-8
10. Shenoy PD, Kumar S, Jha LK, Choudhary SK, Singh U, Mistra R, et al. Efficacy of tadalafil in secondary Raynauds phenomenon resistant to vasodilator therapy: a double-blind randomized crossover trial. Rheumatology 2010;49:2420-8